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Background: According to current guidelines, stroke patients treated with rt-PA
should undergo brain imaging to exclude intracerebral bleeding 24 h after thrombolysis,
before the start of medical secondary prevention. However, the usefulness of routine
follow-up imaging with regard to changes in therapeutic management in patients without
neurological deterioration is unclear. We hypothesized that follow up brain imaging solely
to exclude bleeding in patients who clinically improved after rt-PA application may not
be necessary.
Methods: Retrospective single-center analysis including stroke patients treated with
rt-PA. Records were reviewed for hemorrhagic transformation one day after systemic
thrombolysis and brain imaging-based changes in therapeutic management. Twenty-four
hour after thrombolysis patients were divided into four groups: (1) increased NIHSS score;
(2) unchanged NIHSS score; (3) improved NIHSS score and; (4) NIHSS score = 0.
Results: Out of 188 patients (mean age 73 years, 100 female) receiving rt-PA,
32 (17%) had imaging-proven hemorrhagic transformation including 11 (6%) patients
with parenchymal hemorrhage. Patients in group (1, 2) more often had hypertension
(p = 0.015) and more often had parenchymal hemorrhage (9 vs. 4%; p < 0.206)
compared to group (3, 4) and imaging-based changes in therapeutic management were
more frequent (19% vs. 6%; p = 0.007). Patients of group (3, 4) had no changes in
therapeutic management in 94% of the cases. Patients in group (4) had no hemorrhagic
transformation in routine follow-up brain imaging.
Conclusions: Frequency of hemorrhagic transformation in Routine follow-up brain
imaging and consecutive changes in therapeutic management were different depending
on clinical course measured by NHISS score.
Keywords: thrombolysis, stroke, stroke management, magnetic resonance imaging, computerized tomography,
intracerebral hemorrhage
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INTRODUCTION
Brain imaging 24–36 h after systemic thrombolysis for
acute ischemic stroke is recommended in American Stroke
Association and European Stroke Organization guidelines (1, 2).
Brain imaging is performed to detect secondary bleeding or
hemorrhagic transformation in order to adapt medical stroke
prevention if necessary. Guideline recommendations are based
on the results of the first study on rt-PA (3) demonstrating
rt-PA-related bleeding in 11% of all patients.
According to retrospective observational studies, there is
evidence for the utility of a follow-up CT scan in stroke
patients with clinical signs of deterioration after thrombolysis.
However, the benefit of repeated brain imaging is under
discussion (4–6). On the one hand, clinicians want to confirm
the diagnosis of ischemic stroke, and obtain further information
on lesion location, stroke pattern and size before starting
medical secondary stroke prevention. On the other hand, in the
absence of significant clinical signs, additional imaging places
the patients at risk of, potentially unnecessary, treatment delay
of antiplatelet therapy, causes an interruption in monitoring
and—in case of CT—exposes patients to additional avoidable
radiation. Following these arguments, 3 recent retrospective
single center studies discussed that routine follow-up CT
scan 24 h after thrombolysis may be omitted in selected
patients (7–9):
The aim of our study was to point out if routine follow-
up brain imaging (CT or MRI) 12–36 h after rt-PA treatment
does influence therapeutic management in stroke patients with
or without clinical deterioration. Based on clinical experience,
we hypothesized that follow-up brain imaging is not needed in
stroke patients who clinically improved in the NIHSS score after
rt-PA administration.
MATERIAL AND METHODS
The data supporting the findings of this study are available from
the corresponding author upon reasonable request. Hospitalized
stroke patients treated with rt-PA in 2015 at the Department of
Neurology, Charité–Universitätsmedizin Berlin, Germany were
extracted from a local stroke registry. Data were collected
following a standard procedure and in accordance with the
ethical and privacy policy guidelines of the Charité.
Patients treated with r-tPA for acute stroke who received a
head CT or MRI 12–36 h after rt-PA treatment were included.
Patients who were treated with intra-arterial therapy and with
missing documentation were excluded.
All patients were treated with a rt-PA dosage of 0.9 mg/kg
body weight with a maximal dosage of 90mg rt-PA according
to local regulations. As part of standard care, all stroke patients
were closely monitored on stroke unit. Vital-parameter and
neurological status were monitored and assessed every 6 h
or more frequently. Demographic data, past medical history
and cardiovascular risk factors (i.e., history of hypertension,
hypercholesterolemia, diabetes mellitus and atrial fibrillation)
as well as changes in therapeutic management due to routine
brain imaging 12–36 h after thrombolysis were retrieved from
medical records. Changes in therapeutic management were
predefined as follows: (1) subsequent changes or delay in
medical secondary stroke prevention (antiplatelet therapy [APT],
intravenous or oral anticoagulation [OAC]) for ≥48 h after
repeated brain imaging; (2) surgery because of intracerebral
bleeding (3) any change in blood pressure management after
follow-up brain imaging.
All follow-up brain images were reviewed by a radiologist
or neuro-radiologist as part of routine care. Hemorrhagic
transformation (HT) was stratified into hemorrhagic infarction
(HI) 1 and 2 and parenchymal hematoma (PH) 1 and 2,
respectively, in accordance with the European Cooperative Acute
Stroke Study II (10). In the case of PH bleeding volume was
measured using the ABC/2 method (11).
We divided all patients into 4 groups in accordance to the
calculated change in the NIHSS score between admission and
24 h after systemic thrombolysis as follows: (1) increased NIHSS
score compared to admission; (2) unchanged NIHSS score; (3)
improved NIHSS score and; (4) NIHSS score= 0.
Statistical Analysis
Dichotomized categorical data were compared using Pearson χ2
test or Fisher’s exact test where appropriate. Continuous data
were compared using Mann–Whitney U test or t-Test where
appropriate. We calculated positive predictive values (PPV) and
95%CI for changes in therapeutic management.
For continuous or categorical data with more than 2 groups,
data were compared using Kruskal–Wallis test or Pearson χ2
test where appropriate. All tests were performed at a two-sided
significance level of 0.05 level. As this was an exploratory analysis,
no adjustments were made for multiple comparisons. All tests
were performed via SPSS Version 23 (12). The 95% confidence
intervals for positive predictive values, sensitivity and specificity
were calculated with STATA Version 14 (13).
RESULTS
Baseline Characteristics
We included 226 patients with suspected stroke. Thirty-four
patients who were treated with intra-arterial therapy, 3 patients
with incomplete documentation and 1 patient with death
due to cardiac arrest before follow up brain imaging were
excluded, leaving overall, 188 patients for analysis. In 9 patients
the diagnosis of a stroke mimic was made in the latter
course of disease including follow up brain imaging. Baseline
characteristics of these patients are shown in Table 1. Eighteen
out of 188 patients (10%) had a deterioration according to
NIHSS score within 24 h after systemic thrombolysis (group 1),
60 patients (32%) had no change in the NIHSS score (group 2),
82 (44%) had improvement of the in NIHSS score (group 3), and
28 patients (15%) had an NIHSS score equal to 0 (group 4).
We found differences in baseline characteristics for the
four different groups with regard to prevalence of arterial
hypertension (lowest in group 4), median admissionNIHSS score
(lowest in group 4). Additionally, those with NIHSS score of
0 were on average younger (mean age 67) compared to other
groups (mean age 74), had less often atrial fibrillation (4% vs. 19%
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LABORATORY DIAGNOSTICS (BLOOD) AND CLINICAL PARAMETERS
Age, mean [SD] 73.3 [13.8] 78.3 [13.5] 73.6 [12.7] 74.2 [13.6] 66.9 [15.4] 0.066a
Male sex, % (n) 46.8 (88) 27.8 (5) 50.0 (30) 48.8 (40) 46.4 (13) 0.393b
MRI after 24h, % (n) 65.4 (123) 33.3 (6) 63.3 (38) 67.1 (55) 85.7 (24) 0.004b
NIHSS on admission, median points [IQR] 6[3-13] 9[5-17] 4[2-12] 8[5-16] 3[2-5] <0.001a
eGFR in ml/min/1.73 m2, median [IQR] 68 [50.5–84.5] 58 [54.5–78.5] 72 [47.75–86.75] 62 [50–84] 77 [54–84] 0.572a
HbA1c in %, median [IQR] 5.8 [5.4–6.3] 5.9 [5.4–6.1] 5.8 [5.4–6.2] 5.8 [5.4–6.7] 5.6 [5.1–6.0] 0.311a
SBP at admission in mmHg, median [IQR] 150 [130–170] 148 [129–172] 160 [130–176] 150 [130–170] 150 [130–178] 0.944a
First SBP after thrombolysis in mmHg, median
[IQR]
150 [134–166] 165 [145–187] 156 [136–172] 145 [131–162] 149 [130–170] 0.035a
BS at admission in mmol/l, median [IQR] 6.8 [5.9–8.7] 6.6 [6.2–9.8] 7.0 [6.4–8.8] 6.7 [5.8–8.4] 6.6 [5.8–8.0] 0.580a
First BS after thrombolysis in mg/dl, median
[IQR]
6.7 [5.6–8.1] 6.6[5.6–7.7] 7.2 [5.8–8.4] 6.7 [5.6–8.3] 6.4 [5.5–7.8] 0.634a
CARDIOVASCULAR RISK FACTORS
DM, % (n) 25 (46) 38.9 (7) 26.3 (15) 25.6 (21) 11.1 (3) 0.195b
AHT, % (n) 78.3 (144) 88.2 (15) 75.4 (43) 85.4 (70) 57.1 (16) 0.012b
HLP, % (n) 53.2 (99) 47.1 (8) 55.9 (33) 51.2 (42) 57.1 (16) 0.864b
Previous IS or TIA, % (n) 24.4 (44) 31.3 (5) 31.6 (18) 16 (13) 30.8 (8) 0.131b
CAD % (n) 13.7 (25) 12.5 (2) 15.5 (9) 11.1 (9) 18.5 (5) 0.761b
AFib % (n) 19.1 (35) 23.5 (4) 19.3 (11) 23.2 (19) 3.7 (1) 0.155b
PAOD, % (n) 5 (9) 0 (0) 5.3 (3) 6.2 (5) 3.7 (1) 0.756b
CHF, % (n) 9.4 (17) 12.5 (2) 10.5 (6) 10 (8) 3.7 (1) 0.724b
Nicotin abuse, % (n) 17.4 (32) 22.2 (4) 21.1 (12) 14.6 (12) 14.8 (4) 0.710b
Results are presented as p-values using Pearson Chi squared (b) or Kruskal-Wallis test (a) when appropriate. *24 h after systemic rt-PA application; AFib indicates atrial fibrillation; BS,
blood sugar; CAD, coronary artery disease; CHF, congestive heart failure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HLP, hyper lipoproteinemia; AHT, arterial
hypertension; IS, ischemic stroke; INR, international normalized ratio; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; PAOD, peripheral arterial occlusive
disease; TIA, transient ischemic attack; SBP, systolic blood pressure.
or more), and less often diabetes mellitus (11% vs. 26% or more).
Results are shown in Table 1.
Comparing Stroke Patients With and
Without Clinical Improvement in NIHSS
Score After Thrombolysis
Comparing group 1–2 to group 3–4, differences in baseline
demographics or cardiovascular risk factors were not
statistically significant.
Patients in group 3–4 more often underwent follow-up MRI
(72% vs. 56% in group 1–2, p = 0.031) and had lower systolic
blood pressure values measured directly after the beginning of
thrombolysis (median: 147 mmHg vs. 159 mmHg in group 1–2,
p= 0.015).
Comparing Stroke Patients With and
Without Clinical Deterioration in NIHSS
Score After Thrombolysis
Patients in group 2–4 more often underwent follow-up MRI
(69% vs. 33% in group 1, p = 0.003) and had lower systolic
blood pressure values measured directly after the beginning of
thrombolysis (median: 150 mmHg vs. 165 mmHg in group 1,
p= 0.020).
Location of Ischemic Stroke and HT Type
in Follow-Up Brain Imaging
We found differences in imaging findings in follow-up brain
imaging 12–36 h after thrombolysis for the four different groups
with regard to location of ischemic stroke in the anterior and
medial cerebral artery territory (lowest in group 4), no ischemic
stroke in follow-up brain imaging (highest in group 4), HI2
(highest in group 2), PH2 (highest in group 1). Comparing
group 1–2 to group 3–4, HI2 (10% vs. 1%, p = 0.004) and PH2
(8% vs. 2%, p = 0.049) were found more often in group 1–2
and there was a trend toward a higher volume of PH in group
1–2 missing statistically significance (median volume: 29.5ml
vs. 1.5ml, p = 0.059). Comparing group 1–2 to group 3–4,
differences in location of ischemic stroke were not statistically
significant (Table 4).
Incidence of Other Intracranial
Bleeding Types
In addition to PH on follow-up brain imaging 12–36 h after
thrombolysis, there were 3 patients suffering from concomitant
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No HT 12 (66.6%) 42 (70%) 69 (84.1%) 28 (100%) 0.006
HI 1 (5.5%) 13 (21.7%) 7 (8.5%) 0 (0%) 0.010
PH 5 (27.8%) 2 (3.3%) 4 (4.9%) 0 (0%) <0.001
CHANGES IN THERAPEUTIC MANAGEMENT
Delayed med due to HT in CI 5 (27.8%) 4 (6.7%) 2 (2.4%) 0 (0%) 0.000
Any change in BP management due
to HT in CI
4 (22.2%) 8 (13.3%) 6 (7.3%) 0 (0%) 0.051
Changes in therapeutic management
due to HT in CI
5 (27.8%) 10 (16.7 %) 7 (8.5%) 0 (0%) 0.015
NIHSS deterioration or
no change* (n = 78)
NIHSS improvement or
NIHSS = 0* (n = 110)
IMAGING FINDINGS
No HT 54 (69.2%) 97 (88.2%) 0.002
HI 14 (17.9%) 7 (6.4%) 0.013
PH 7 (9.0%) 4 (3.6%) 0.0124
CHANGES IN THERAPEUTIC MANAGEMENT
Delayed med due to HT in FU-BI 9 (11.5%) 2 (1.8%) 0.005
Any change in BP management due to HT in FU-BI 12 (15.4%) 6 (5.4%) 0.023
Changes in therapeutic management due to HT in FU-BI 15 (19.2%) 7 (6.4%) 0.007
NIHSS deterioration*
(n = 18)
No Change in NIHSS,
NIHSS improvement or
NIHSS = 0* (n = 170)
IMAGING FINDINGS
No HT 12 (66.6%) 144 (84.7%) 0.053
HI 1 (5.5%) 20 (11.8%) 0.426
PH 5 (27.8%) 6 (3.5%) <0.001
CHANGES IN THERAPEUTIC MANAGEMENT
Delayed med due to HT in FU-BI 5 (27.8%) 6 (3.6%) <0.001
Any change in BP management due to HT in FU-BI 4 (22.2%) 14 (8.2%) 0.055
Changes in therapeutic management due to HT in FU-BI 5 (27.8%) 17 (10%) 0.026
NIHSS deterioration, no
change in NIHSS or
NIHSS improvement*
(n = 160)
NIHSS = 0* (n = 28)
IMAGING FINDINGS
No HT 128 (80%) 28 (100%) 0.009
HI 21 (13.1%) 0 (0%) 0.042
PH 11 (6.9%) 0 (0%) 0.153
CHANGES IN THERAPEUTIC MANAGEMENT
Delayed med due to HT in FU-BI 11 (6.9%) 0 (0%) 0.153
Any change in BP management due to HT in FU-BI 18 (11.3%) 0 (0%) 0.062
Changes in therapeutic management due to HT in FU-BI 22 (13.8%) 0 (0%) 0.037
The results of dichotomiced data regarding follow-up brain imaging findings for hemorrhagic transformation and management changes are given in this table. Results are presented
as p-values using Pearson Chi squared or Fisher exact test when appropriate. There was no patient with cranial surgery due to hemorrhagic transformation in follow-up brain imaging.
*24 h after systemic rt-PA application; BP indicates blood pressure; Delayed Med, delayed medication for more than 48 h after intravenous thrombolysis (anti-platelet therapy or
anticoagulation); FU-BI, routine follow-up brain imaging after 12–36 h; HI, Hemorrhagic infarction; HT, hemorrhagic transformation; NIHSS, National Institutes of Health Stroke Scale;
PH, Parenchymal hematoma.
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intraventricular hemorrhage (IVH) and 2 patients sustaining
concomitant subarachnoid hemorrhage (SAH). One of three
patients sustaining IVH had a neurological deterioration evident
in NIHSS scoring and the other 2 patients remained clinically
TABLE 3 | Sensitivity, specificity, positive and negative predictive value of


































The sensitivity, specificity and positive predictive value of improvement in NIHSS [Group
(3, 4)] for imaging findings and changes in therapeutic management due to hemorrhagic
transformation in routine follow-up brain imaging after 12–36 h are given in this table.
Results are presented in percentages using STATA 14 for determination of confidence
intervals. *in routine follow-up brain imaging after 12–36 h. CI indicates confidence interval;
HI, hemorrhagic infarction; HT, hemorrhagic transformation; NIHSS, National Institutes of
Health Stroke Scale; NPV, negative predictive value; PH, parenchymal hematoma; PPV,
positive predictive value.
stable. Both patients with concomitant SAH deteriorated within
24 h after IVT application.
In one case, the diagnosis of amyloid angiopathy was newly
made on the basis of multiple microbleeds seen on MRI on
admission. This patient neurologically improved as captured on
the NIHSS within 24 h but follow-up imaging revealed a PH2
(volume 2.1 ml).
Impact of HT on Changes in
Therapeutic Management
Patients in group 2–4 had significantly less often changes in
therapeutic management compared to group 1 (10% vs. 28%;
p = 0.026, Table 2), The positive predictive value (PPV) for
no changes in therapeutic management was 90% (95%CI: 84.5–
94.1%) with a sensitivity of 92% (95%CI: 87.0–95.8%) and a
specificity of 23% (95%CI: 7.8–45.4%).
Patients in group 3–4 had even less often changes in
therapeutic management compared to patients in group 1–2
(6% vs. 19%; p = 0.007, Table 2). The PPV for no changes in
therapeutic management was 94% (95%CI: 87.3–97.4%, Table 3)
with a sensitivity of 62% (95%CI: 54.2–69.5%, Table 3) and a
specificity of 68% (95%CI: 45.1–86.1%, Table 3).
Patients in group 4 had no HT and hence significantly less
often management changes compared to patients in group 1–3
(0% vs. 14%; p = 0.037, Table 2). The PPV for no changes in
therapeutic management was 100% (95%CI: 87.7–100%) with a
TABLE 4 | Imaging findings and stroke location due to routine follow-up brain imaging after 12–36 h.
Imaging findings NIHSS deterioration*
(n = 18)











IS in ACA or MCA territory 14 (77.8%) 36 (60.0%) 55 (67.1%) 8 (28.6%) 0.001a
IS in vertebrobasilar territory 3 (16.7%) 18 (30.0%) 28 (34.1%) 6 (21.4%) 0.366a
No IS in FU-BI 1 (5.6%) 10 (16.7%) 8 (9.8%) 16 (57.1%) <0.001a
HI 1 1 (5.6%) 5 (8.3%) 6 (7.3%) 0 (0%) 0.488a
HI 2 0 (0%) 8 (13.3%) 1 (1.2%) 0 (0%) 0.003a
PH 1 1 (5.6%) 0 (0%) 2 (2.4%) 0 (0%) 0.309a
PH 2 4 (22.2%) 2 (3.3%) 2 (2.4%) 0 (0%) 0.001a
Volume of PH in ml, median
[IQR]
87.9 [15.1–112.1] 14.2 [5.6–n.a.] 1.5 [0.7–9.6] n.a. 0.129b
Imaging findings NIHSS deterioration or no change* (n = 78) NIHSS improvement or NIHSS = 0* (n = 110)
IS in ACA or MCA territory 50 (64.1%) 63 (57.3%) 0.346a
IS in vertebrobasilar territory 21 (26.9%) 34 (30.9%) 0.554a
No IS in FU-BI 11 (14.1%) 24 (21.8%) 0.181a
HI 1 6 (7.7%) 6 (5.5%) 0.536a
HI 2 8 (10.3%) 1 (0.9%) 0.003a
PH 1 1 (1.3%) 2 (1.8%) 0.773a
PH 2 6 (7.7%) 2 (1.8%) 0.049a
Volume of PH in ml, median [IQR] 29.5 [5.6–95.4] 1.5 [0.6–13.4] 0.059c
Results are presented as p-values using χ2 Pearson (a), Kruskal-Wallis (b) or Mann–Whitney U test (c) when appropriate. *24 h after systemic rt-PA application; ACA, anterior cerebral
artery; FU-BI, routine follow-up brain imaging after 12–36 h; HI, Hemorrhagic infarction; IS, ischemic stroke; MCA, medial cerebral artery; NIHSS, National Institutes of Health Stroke
Scale; PH, Parenchymal hematoma.
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sensitivity of 17% (95%CI: 11.5–23.4%) and a specificity of 100%
(95%CI: 84.6–100%).
In a sub analysis excluding the 9 patients who were diagnosed
as stroke mimics in the latter course of the hospital stay, the PPV
for no changes in therapeutic management in group 1 vs. group
2–4 was 89% (28% vs. 11% p= 0.035), in group 1–2 vs. group 3–4
93% (20% vs.7% p = 0.008) and in group 1–3 vs. group 4 100%
(14% vs. 0% p= 0.061).
DISCUSSION
Diagnosis and treatment decisions in stroke require brain
imaging. Following treatment with rt-PA, guidelines recommend
to repeat brain imaging 24–36 h after application.
The reasons to conduct imaging after acute stroke
treatment are multiple; only one of them is to understand
hemorrhagic evolution. Others include understanding mass
effect, considering the need for hemicraniectomy or osmotic
therapy, understanding prognosis, planning rehabilitation and
confirm diagnosis. In case of clinical worsening during or
after thrombolysis immediate brain imaging is performed
in clinical practice specially to exclude a hemorrhage.
In patients who tolerated rt-PA well and demonstrated
improvement, the question remains, whether this obligatory
follow-up brain-imaging is necessary before starting secondary
prevention treatment.
Comparing present literature (7–9), our study has a similar
sample size compared to other reports, but answers more
specifically clinically relevant aspects:
Dharamasaroja et al were the first who questioned the
need for a follow-up CT after rt-PA treatment in patients
with early clinical/neurological improvement, based on a
retrospective study including 200 stroke patients. However,
they did not mention any clinical impact (7). Furthermore,
George et al. reported similar results as our study, based
on a retrospective analysis including 200 patients, but did
not describe the changes in therapeutic management in the
subgroups who had findings of bleeding on imaging (8).
Moreover, Guhwe et al. reported that clinicians changed the
therapeutic management following routine CT scans in just
one out of 136 clinically stable stroke patients. However, they
reported solely alterations in blood pressure management as
a change in therapeutic management after HT in follow-
up brain imaging. No other changes in management were
documented (9). In a recently published abstract, Sevilis
et al. analyzed 280 stroke patients after rt-PA and showed
in 5% a delay in initiation of antithrombotic medication
for asymptomatic patients due to follow-up brain imaging.
However, the data has not been published (14) yet. To date,
our study is the only one that considered several aspects
of changes in therapeutic management, such as delay in
antiplatelet agents or oral anticoagulation, blood pressure
management, or neurosurgical interventions in relation to HT
after thrombolytic treatment.
Our cohort showed more frequent changes in therapeutic
management of asymptomatic patients due to HT in follow-up
brain imaging (10%) compared to Guhwe et al. (1 out of
136 patients) and Sevilis et al. (5% of delay in antithrombotic
medication, unpublished data).
In our cohort, the number of overall HT in follow-up brain
imaging in the case of clinical improvement in the NIHSS score
after 24 h was 10% with no cases of other bleeding types such
as IVH and SAH. This information leaded in 6% of this group
to an overall change in therapeutic management and in 2% to a
delay in the start of medical secondary prevention. In the case of
complete recovery in the NIHSS score after 24 h no HT occurred
in follow-up brain Imaging.
As already mentioned, a control image is not only used
to exclude bleeding, but this would be one of the most
important reasons for delaying secondary prevention therapy.
After thrombolytic treatment in case of hemorrhage, mass effect
by malignant cerebral infract or other pathologies, a clinical
improvement is unlikely to be expected.
Our data imply that the use of routine follow up brain imaging
could be avoided in the case of complete clinical recovery in
NIHSS, avoiding, in the case of CT, radiation exposure and above
all costs.
However, with 6% of overall changes in therapeutic
management due to HT in the case of clinical improvement
in NIHSS score, prospective studies are needed to further
investigate the impact of these management changes on
therapeutic outcome before conclusions could be drawn.
This study has several limitations: (a) data were assessed
retrospectively in a single tertiary care University hospital.
Although patient care was based on European and National
guidelines, variations in clinical practice (e.g., availability of
MRI) exist and the results may not be generalizable to other
care settings; (b) the number of patients in our cohort is
limited in certain subgroups and hence, prospective studies
are needed to validate our findings; (c) the percentage of
patients undergoing MRI varied across subgroups; (d)despite
its proven validity the NIHSS score has certain limitations and
may fail to assess clinical alterations in patients with posterior
circulation stroke (15); (e) the proportion of patients with mild
strokes in our study was high with a median NIHSS of 6
and our results may not be generalized to patients with more
severe strokes who frequently persist with important deficits
despite improvement.
SUMMARY
In patients with complete recovery in NIHSS score within 24 h
after thrombolysis, routine follow up brain imaging seems not to
be mandatory before starting secondary prevention.
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